Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
The summit also saw the launch of two important reports- Multi-Regional Clinical Trials (MRCT) and Value of OTC in India
Voluntary nationwide recall of lots of Accuretic (quinapril HCl/hydrochlorothiazide), quinapril and hydrochlorothiazide tablets, and quinapril HCl/hydrochlorothiazide tablets due to n-nitroso- quinapril content
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
